BLTE
USDBelite Bio Inc American Depositary Shares
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$114.150
Kõrge
$114.440
Madal
$112.000
Maht
0.08M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
4.0B
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
0.07M
Börs
NCM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have
Belite Bio Announces UK's Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
MHRA response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025 SAN DIEGO, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), a clinical-stage drug
Benchmark Maintains Buy on Belite Bio, Raises Price Target to $132
Benchmark analyst Bruce D. Jackson maintains Belite Bio with a Buy and raises the price target from $80 to $132.
Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ:BLTE) ("Belite" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal
Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ:BLTE) ("Belite" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal
Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
NMPA's response is based on the Phase 3 DRAGON interim analysis resultsTopline final data expected in Q4 2025 SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), a clinical-stage drug
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.